Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965021 | 0.91 | KDM4E (0.65) | KDM4ETDP1ALDH1A1KMT2ACCR5 | |
| SCHEMBL19869696 | 0.85 | TRPV6 (0.54) | KDM4ETDP1TRPV6ALDH1A1KMT2A | |
| SCHEMBL6604508 | 0.80 | KDM4E (0.80) | KDM4ETDP1TRPV6ALDH1A1KMT2A | |
| SCHEMBL1427564 | 0.79 | KDM4E (0.83) | KDM4ETDP1TRPV6ALDH1A1KMT2A | |
| SCHEMBL24556573 | 0.78 | TRPV6 (0.47) | KDM4ETDP1TRPV6ALDH1A1KMT2A | |
| SCHEMBL19869956 | 0.78 | GAA (0.66) | KDM4ETDP1TRPV6ALDH1A1KMT2A | |
| SCHEMBL4591936 | 0.77 | KDM4E (0.70) | KDM4ETDP1TRPV6ALDH1A1KMT2A | |
| SCHEMBL29964963 | 0.77 | KDM4E (0.70) | KDM4ETDP1TRPV6ALDH1A1KMT2A | |
| SCHEMBL19869936 | 0.77 | TRPV6 (0.52) | KDM4ETDP1TRPV6ALDH1A1KMT2A | |
| SCHEMBL18227502 | 0.77 | KDM4E (0.61) | KDM4ETDP1TRPV6ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BRD9, BRD1, BRD2 | KDM4E 1154/4885TDP1 1473/4885TRPV6 3899/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | KDM4E 1262/4885TDP1 1708/4885TRPV6 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.